1. Home
  2. SURG vs BCAB Comparison

SURG vs BCAB Comparison

Compare SURG & BCAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo SurgePays Inc.

SURG

SurgePays Inc.

HOLD

Current Price

$0.22

Market Cap

6.4M

ML Signal

HOLD

Logo BioAtla Inc.

BCAB

BioAtla Inc.

HOLD

Current Price

$3.29

Market Cap

5.9M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SURG
BCAB
Founded
2006
2007
Country
United States
United States
Employees
20
N/A
Industry
Advertising
Medicinal Chemicals and Botanical Products
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
6.4M
5.9M
IPO Year
N/A
2020

Fundamental Metrics

Financial Performance
Metric
SURG
BCAB
Price
$0.22
$3.29
Analyst Decision
Strong Buy
Hold
Analyst Count
1
1
Target Price
$5.00
N/A
AVG Volume (30 Days)
7.4M
38.8K
Earning Date
04-14-2026
05-08-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
29.86
EPS
N/A
N/A
Revenue
N/A
$300,000.00
Revenue This Year
$136.77
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.22
$0.12
52 Week High
$3.22
$6.52

Technical Indicators

Market Signals
Indicator
SURG
BCAB
Relative Strength Index (RSI) 29.61 42.09
Support Level N/A $3.28
Resistance Level $0.94 $4.24
Average True Range (ATR) 0.03 0.28
MACD -0.00 -0.06
Stochastic Oscillator 3.77 10.23

Price Performance

Historical Comparison
SURG
BCAB

About SURG SurgePays Inc.

Surgepays Inc is a wireless and point of sale technology company focused on serving underserved and value-conscious consumers through a combination of retail distribution and digital acquisition channels. It provides mobile connectivity, financial technology services, and transaction processing solutions through an integrated platform that combines wireless services with point of sale software and retail distribution. It enables in-store and online activation of wireless services, prepaid top-ups, and financial transactions, allowing consumers to access essential services in both local and digital environments. Its segments are wireless services or MVNO Telecommunications, platform services or MVNE Enablement Platform (HERO), and wholesale enablement or Comprehensive Platform Services.

About BCAB BioAtla Inc.

BioAtla Inc is a clinical-stage biopharmaceutical company. The company is engaged in the development of a novel class of specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its pipeline products comprise mecbotamab vedotin (BA3011), ozuriftamab vedotin (BA3021), and evalstotug (BA3071), and its Phase 1 clinical trial of BA3182 (CAB-EpCAM x CAB-CD3) and Bispecific antibody programs. The company's operations are organized on a single reportable segment, which includes all activities related to the discovery, development, and commercialization of its CAB products.

Share on Social Networks: